Tirzepatide is a dual GLP-1 and GIP receptor agonist, approved by the Food and Drug Administration (FDA) and later by the European Medicines Agency (EMA) for T2DM [58,85]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.